Synthesis, morphological structures, and material characterization of electrospun PLA:PCL/Magnetic nanoparticle composites for drug delivery

2013 ◽  
pp. n/a-n/a ◽  
Author(s):  
Hazim J. Haroosh ◽  
Yu Dong ◽  
Gordon D. Ingram
Keyword(s):  
Drug Delivery ◽  
Material Characterization ◽  
Magnetic Nanoparticle ◽  
Nanoparticle Composites

Preparation and Characterization of Fe3O4 Magnetic Nanoparticles Labeled with Technetium-99m Pertectnetate

2013 ◽  
Vol 459 ◽  
pp. 51-59 ◽  
Author(s):  
Chang Shu Tsai ◽  
Wei Chung Liu ◽  
Hong Yi Chen ◽  
Wei Chun Hsu
Keyword(s):  
Drug Delivery ◽  
Magnetic Nanoparticles ◽  
Targeted Drug Delivery ◽  
Magnetic Nanoparticle ◽  
Drug Carrier ◽  
Precipitation Method ◽  
Technetium 99M ◽  
Reducing Ability ◽  
Targeted Drug

In the aspect of biomedical diagnosis, magnetic nanoparticle can be used as drug carrier and MRI/ SPECT/ PET contrast agents. Magnetic fluid hyperthermia is one of the most important cancer therapies. Magnetic nanoparticles display their unique features as heating mediators for hyperthermia. In this study, Fe3O4magnetic nanoparticle was prepared by using chemical co-precipitation method. Tc-99m pertechnetate with Fe3O4magnetic nanoparticles is prepared by using magnet adsorption method. An attempt was also made to evaluate the application in the field of magnetic targeted drug delivery and radioactive targeted cancer treatment in the future. In this work, preparation and characterization of non-polymer and polymer (dextran) coated Fe3O4magnetic nanoparticles labeled with technetium-99m pertectnetate were evaluated and served as precursors study. The Tc-99m labeling efficiency of in-house Fe3O4magnetic nanoparticles (MNP) and commercial kit were ca.98.4 % and 85% (n=5), under the same conc. of 6mM, 0.1 ml of SnCl2·2H2O, respectively. The Tc-99m labeling efficiency of magnetic nanoparticles with its dextran-coated was ca. 58.2% (n=5) at the same conc. and volume of SnCl2·2H2O. The in-vitro stabilities of the 3 kinds of magnetite magnetic fluids were higher than 96.0% (n=5) during 2 hours. The reducing agent of SnCl2·2H2O plays a key role due to its reducing ability for Tc-99m pertechnetate. The optimal reaction time of SnCl2·2H2O with Tc-99m is better under 1 hour. In conclusion, the Fe3O4magnetic nanoparticle labeled with Tc-99m pertechnetate has shown good qualities for its labeling efficiency and stability. It may be feasible preliminary to utilize in the application of magnetic targeted drug delivery of bio-medicine.

Biopolymers with Medical Applications Optimized method for obtaining chitosan-based delivery systems

2018 ◽  
Vol 69 (7) ◽  
pp. 1756-1759 ◽  
Author(s):  
Luminita Confederat ◽  
Iuliana Motrescu ◽  
Sandra Constantin ◽  
Florentina Lupascu ◽  
Lenuta Profire
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Average Diameter ◽  
Delivery Systems ◽  
Cross Linking ◽  
Low Molecular Weight ◽  
Polymeric Systems ◽  
Chitosan Microparticles ◽  
Degree Of Swelling

The aim of this study was to optimize the method used for obtaining microparticles based on chitosan � a biocompatible, biodegradable, and nontoxic polymer, and to characterize the developed systems. Chitosan microparticles, as drug delivery systems were obtained by inotropic gelation method using pentasodiumtripolyphosphate (TPP) as cross-linking agent. Chitosan with low molecular weight (CSLMW) in concentration which ranged between 0.5 and 5 %, was used while the concentration of cross-linking agent ranged between 1 and 5%. The characterization of the microparticles in terms of shape, uniformity and adhesion was performed in solution and dried state. The size of the microparticles and the degree of swelling were also determined. The structure and the morphology of the developed polymeric systems were analyzed by Fourier transform infrared spectroscopy (FTIR) and scanning electron microscopy (SEM).The average diameter of the chitosan microparticles was around 522 �m. The most stable microparticles were obtained using CSLMW 1% and TPP 2% or CSLMW 0.75%and TPP 1%. The micropaticles were spherical, uniform and without flattening. Using CSLMW in concentration of 0.5 % poorly cross-linked and crushed microparticles have been obtained at all TPP concentrations. By optimization of the method, stable chitosan-based micropaticles were obtained which will be used to develop controlled release systems for drug delivery.

Hydrogel-clay Nanocomposites as Carriers for Controlled Release

2020 ◽  
Vol 27 (6) ◽  
pp. 919-954 ◽  
Author(s):  
Raluca Ianchis ◽  
Claudia Mihaela Ninciuleanu ◽  
Ioana Catalina Gifu ◽  
Elvira Alexandrescu ◽  
Cristina Lavinia Nistor ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Controlled Release ◽  
Hybrid Materials ◽  
Pharmaceutical Formulations ◽  
Tree Of Life ◽  
Present Review ◽  
Clay Nanocomposites ◽  
Delivery Platform ◽  
Complex Hybrid

The present review aims to summarize the research efforts undertaken in the last few years in the development and testing of hydrogel-clay nanocomposites proposed as carriers for controlled release of diverse drugs. Their advantages, disadvantages and different compositions of polymers/biopolymers with diverse types of clays, as well as their interactions are discussed. Illustrative examples of studies regarding hydrogel-clay nanocomposites are detailed in order to underline the progressive researches on hydrogel-clay-drug pharmaceutical formulations able to respond to a series of demands for the most diverse applications. Brief descriptions of the different techniques used for the characterization of the obtained complex hybrid materials such as: swelling, TGA, DSC, FTIR, XRD, mechanical, SEM, TEM and biology tests, are also included. Enlightened by the presented data, we can suppose that hydrogel-clay nanocomposites will still be a challenging subject of global assiduous researches. We can dare to dream to an efficient drug delivery platform for the treatment of multiple affection concomitantly, these being undoubtedly like ”a tree of life” bearing different kinds of fruits and leaves proper for human healing.

scholarly journals Focused ultrasound in neuro-oncology: the role of the Focused Ultrasound Foundation in driving adoption and innovation

2021 ◽  
Author(s):  
Emily C. Whipple ◽  
Camille A. Favero ◽  
Neal F. Kassell
Keyword(s):  
Drug Delivery ◽  
Brain Tumors ◽  
Focused Ultrasound ◽  
Clinical Evidence ◽  
Neurological Injury ◽  
High Concentration ◽  
Potential Applications ◽  
Tumor Agent

Abstract Introduction Intra-arterial (lA) delivery of therapeutic agents across the blood-brain barrier (BBB) is an evolving strategy which enables the distribution of high concentration therapeutics through a targeted vascular territory, while potentially limiting systemic toxicity. Studies have demonstrated lA methods to be safe and efficacious for a variety of therapeutics. However, further characterization of the clinical efficacy of lA therapy for the treatment of brain tumors and refinement of its potential applications are necessary. Methods We have reviewed the preclinical and clinical evidence supporting superselective intraarterial cerebral infusion (SSJACI) with BBB disruption for the treatment of brain tumors. In addition, we review ongoing clinical trials expanding the applicability and investigating the efficacy of lA therapy for the treatment of brain tumors. Results Trends in recent studies have embraced the use of SSIACI and less neurotoxic chemotherapies. The majority of trials continue to use mannitol as the preferred method of hyperosmolar BBB disruption. Recent preclinical and preliminary human investigations into the lA delivery of Bevacizumab have demonstrated its safety and efficacy as an anti-tumor agent both alone and in combination with chemotherapy. Conclusion lA drug delivery may significantly affect the way treatment are delivered to patients with brain tumors, and in particular GBM. With refinement and standardization of the techniques of lA drug delivery, improved drug selection and formulations, and the development of methods to minimize treatment-related neurological injury, lA therapy may offer significant benefits for the treatment of brain tumors.

Sign in / Sign up

Export Citation Format

Share Document